Viveve Medical plunges as urinary disease drug fails to meet main goal

Viveve Medical

17/01/2023 13:06

** Viveve Medical Inc's shares  VIVE.O  plunge 66.5% to
$0.29 - biggest pct. loser across U.S. stock exchanges premarket
    ** Women's health-focused medical device maker says its
treatment for stress urinary incontinence failed to meet main
goal in a pivotal study - SEC filing
    ** VIVE seeks strategic alternatives and will delist from
Nasdaq 
    ** Co to also reduce workforce, resulting in a charge of
$25,000 in Q1 2023 - SEC filing
    ** VIVE shares fell ~63% in last 12 months
 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))